Ole Andreas Halvorsen
Viking Global Investors
Ole Andreas Halvorsen NEWAMSTERDAM PHARMA CO NV stake
total: 670
Viking Global Investors NAMS trades
- Total transactions:
- 7
- New positions:
- 1
- Added:
- 3
- Reduced:
- 3
- Held since:
- 2022 Q4
- Held for:
- 15 quarters
- Latest activity:
- 2025 Q4
According to 2026 Q2 report, Ole Andreas Halvorsen holds 4,203,567 NEWAMSTERDAM PHARMA CO NV (NAMS) shares with a market value of roughly $142.46M accounting for 0.41% of the overall portfolio. To date, the estimated cost basis is nearly $10.79 for "buy" trades and estimated average "sell" price is $31.64. Viking Global Investors first purchased NAMS in 2022 Q4, initially acquiring about 3.75M shares. Since the initial investment in NEWAMSTERDAM PHARMA CO NV (NAMS), Viking Global Investors has made 6 more transactions.
When did Ole Andreas Halvorsen buy NEWAMSTERDAM PHARMA CO NV (NAMS)?
Ole Andreas Halvorsen first invested in NEWAMSTERDAM PHARMA CO NV (NAMS) in 2022 Q4 at the reported quarter-end price of $10.52 per share.
What's the cost basis of Viking Global Investors's NAMS stake?
The estimated cost basis for NEWAMSTERDAM PHARMA CO NV (NAMS) stake is around $10.79 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $10.79
- Weighted AVG sell price:
- $31.64
Ole Andreas Halvorsen's historical trades in NEWAMSTERDAM PHARMA CO NV
7 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2025 Q4
|
0.39%
|
4,203,567
|
$35.08
|
$147,461,130
|
-35.09% (-2,271,967)
|
-0.21%
|
|
2025 Q3
|
0.48%
|
6,475,534
|
$28.44
|
$184,164,187
|
-7.21% (-503,000)
|
-0.04%
|
|
2024 Q4
|
0.58%
|
6,978,534
|
$25.70
|
$179,348,324
|
-13.04% (-1,046,031)
|
-0.1%
|
|
2023 Q3
|
0.30%
|
8,024,565
|
$9.25
|
$74,227,226
|
+22.99% (+1,500,000)
|
+0.06%
|
|
2023 Q2
|
0.32%
|
6,524,565
|
$11.89
|
$77,577,078
|
+66.62% (+2,608,695)
|
+0.13%
|
|
2023 Q1
|
0.25%
|
3,915,870
|
$13.44
|
$52,629,293
|
+4.32% (+162,042)
|
+0.01%
|
|
2022 Q4
|
0.20%
|
3,753,828
|
$10.52
|
$39,490,271
|
new
|
+0.2%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.